CDMO Pharmaceutics International (Pii) has invested $3.6m into its prefilled syringe production capabilities.
This will cover advancements in the company's fill/finish, automated visual inspection technologies and advanced labelling capabilities.
This follows the uptick in demand for prefilled syringe solutions within the pharmaceutical and biotech industries, which Pii intends to meet via its end-to-end drug manufacturing services.
Through this investment, Pii will incorporate a syringe labeller from Optima, as well as a automated visual inspection system from Antares.
Optima's syringe labeller, which is currently being installed at Pii's Hunt Valley site in Maryland, US, will be fully operational by the early second half of 2025, Pii estimates.
The machinery will automate vital stages of the process, including syringe labelling, plunger insertion and safety device integration.
Novel AVI technology from Antares will likely be ready for commercial use by quarter three of 2025, which which facilitate the automation of the quality control inspection process.
The system can identify particles, cracks, air bubbles and fill-level issues, ensuring that all prefilled syringes are safe and of a high quality.
By combining fill/finish capabilities with automation technologies, Pii hope to remove the need for multiple CDMOs, reducing the complexity of the injectable manufacturing process.
CEO of Pii, John Fowler, commented: “With this expansion, Pii strengthens its role as a comprehensive partner, allowing clients to achieve faster time-to-market by managing every step of the PFS process,”
“Our streamlined approach will support customers in optimizing both cost and quality, meeting stringent regulatory demands, and ultimately improving patient access to essential therapies.”